2 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Journal of the American Academy of Dermatology
Volume 57, n° 4
pages 683-689 (octobre 2007)
Doi : 10.1016/j.jaad.2007.02.027

Thymoma-associated multiorgan autoimmunity: A graft-versus-host–like disease

Akhil Wadhera, MD a, b, Emanual Maverakis, MD b, Nicholas Mitsiades, MD c, Primo N. Lara, MD d, Maxwell A. Fung, MD a, e, Peter J. Lynch, MD b,
a Permanente Medical Group, Fremont, California 
b Department of Dermatology, University of California Davis, Sacramento, California 
d Department of Internal Medicine, University of California Davis, Sacramento, California 
e Department of Pathology, University of California Davis, Sacramento, California 
c Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 

Reprint requests: Peter J. Lynch, MD, Department of Dermatology, University of California Davis, 3301 C St, Suite 1412, Sacramento, CA 95816.

Graft-versus-host disease (GVHD) is a T cell–mediated disease seen most commonly after hematopoietic stem cell transplantation. Rarely, a GVHD-like disease can be seen in patients with malignant thymoma. We describe a 50-year-old man with malignant thymoma who developed skin, liver, and intestinal manifestations similar to that seen in GVHD. We also review other reported cases of GVHD-like manifestations in the setting of thymoma and propose “thymoma-associated multiorgan autoimmunity” as a name for this novel disease. Specifically, thymoma-associated multiorgan autoimmunity is defined as a disease of the liver, intestine, or skin, which on histopathology resembles GVHD but is seen in the setting of malignant thymoma and not after hematopoietic stem cell transplantation.

The full text of this article is available in PDF format.

Abbreviations used : GVHD, HSCT, MHC, Ta, TAMA

 A. Wadhera coordinated the dermatologic treatment of the patient and prepared Table I. E. Maverakis wrote the manuscript, collected data for the publication, and coined the new disease name TAMA. P. Lynch proposed GVHD as the patient’s diagnosis and collected data for the publication. M. Fung interpreted the dermatopathology. N. Mitsiades served as a source of technical expertise and helped in revising the manuscript. P. Lara was the oncologist. He served as a source of technical expertise. All authors proofed the manuscript and made suggestions during its preparation.
 Funding sources: None.
 Conflicts of interest: None declared.

© 2007  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline
You can move this window by clicking on the headline